Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05672615 · ClinicalTrials.gov registry record
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
A clinical trial of Non-muscle Invasive Bladder Cancer, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- 42
- Enrollment target
- 1
- Study location
NCT05672615 is a study of Non-muscle Invasive Bladder Cancer that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 42 participants, below the 232-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05672615, a study of Non-muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer receiving intravesical treatments are eligible to participate in this study. Participation involves providing research blood and urine samples prior to the start of treatment and throughout the treatment course. The study team will also collect participant's medical history and clinical information. Participants will be asked to complete questionnaires and daily mood diaries.
Conditions Studied
Interventions
- OTHER Questionnaires
- OTHER Daily Mood Diaries
- OTHER Urine Specimen Collection
- OTHER Research Blood Draw
- OTHER Utilize excess tissue from a standard of care procedure
Study Locations (1)
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-03-21 |
| Est. Completion | 2028-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05672615
The ClinicalTrials.gov registry entry for NCT05672615 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 5 interventions - of which Questionnaires is the first listed.
NCT05672615 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05672615 about?
NCT05672615 is a clinical study titled "Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG". The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer receiving intravesical treatments are eligible to participate in this study. Partic...
What is the current status of trial NCT05672615?
This trial is currently recruiting. The enrollment target is 42 participants. The study started on 2023-03-21. Estimated completion is 2028-03.
What conditions does trial NCT05672615 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.
What interventions are being tested in trial NCT05672615?
The interventions under investigation include: Questionnaires (OTHER), Daily Mood Diaries (OTHER), Urine Specimen Collection (OTHER), Research Blood Draw (OTHER), Utilize excess tissue from a standard of care procedure (OTHER).
Who is sponsoring clinical trial NCT05672615?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05672615 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RECRUITING · Phase 1
-
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
-
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
RECRUITING · Phase 2
-
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.